Core Viewpoint - The company Shijiazhuang Pharmaceutical Group has received production registration approvals from the National Medical Products Administration for seven pharmaceutical products, indicating a significant advancement in its product portfolio and market positioning [1]. Group 1: Product Approvals - The company has obtained approvals for the following products: 1. Arginine Perindopril Tablets (10mg), classified as a Class 4 chemical drug, is the second domestic company to receive approval, primarily used for treating hypertension and congestive heart failure [1]. 2. Progesterone Injection (II) (1.112ml:25mg), classified as a Class 3 chemical drug, is used for progesterone supplementation in assisted reproductive technology (ART) [1]. 3. Labetalol Hydrochloride Injection (20ml:100mg), classified as a Class 3 chemical drug, is used for various types of hypertension, especially hypertensive crises, and for blood pressure control before surgery [1]. 4. Calcium Chloride Injection (10ml:1g), classified as a Class 3 chemical drug, is primarily used for treating acute hypocalcemia and magnesium poisoning [1]. 5. Compound Electrolyte Acetate Injection (500ml), classified as a Class 3 chemical drug, is used for treating isotonic dehydration with mild acidosis and for replenishing extracellular fluid and blood volume loss [1]. 6. Compound Electrolyte Injection (V) (500ml), classified as a Class 3 chemical drug, serves as a source of water and electrolytes for adults [1]. 7. Levosalbutamol Hydrochloride Nebulization Solution (3ml:0.63mg), classified as a Class 3 chemical drug, is used for treating or preventing bronchospasm in adults and children over six years old with reversible airway obstructive diseases [1].

Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group, has received production registration approvals from the National Medical Products Administration for seven pharmaceutical products, indicating a significant advancement in its product portfolio and market positioning [1]. Group 1: Product Approvals - The company has obtained approvals for the following seven drugs: 1. Arginine Perindopril Tablets (10mg), classified as a Class 4 chemical drug, is the second domestic company to receive approval, primarily used for treating hypertension and congestive heart failure [1]. 2. Progesterone Injection (II) (1.112ml: 25mg), classified as a Class 3 chemical drug, is used for progesterone supplementation in assisted reproductive technology (ART) [1]. 3. Labetalol Hydrochloride Injection (20ml: 100mg), classified as a Class 3 chemical drug, is indicated for various types of hypertension, especially hypertensive crises, and for blood pressure control before surgery [1]. 4. Calcium Chloride Injection (10ml: 1g), classified as a Class 3 chemical drug, is primarily used for treating acute hypocalcemia and magnesium poisoning [1]. 5. Compound Electrolyte Acetate Injection (500ml), classified as a Class 3 chemical drug, is used for treating isotonic dehydration with mild acidosis and for replenishing extracellular fluid and blood volume loss [1]. 6. Compound Electrolyte Injection (V) (500ml), classified as a Class 3 chemical drug, serves as a source of water and electrolytes for adults [1]. 7. Levosalbutamol Nebulization Solution (3ml: 0.63mg), classified as a Class 3 chemical drug, is used for treating or preventing bronchospasm in adults and children over 6 years old with reversible airway obstructive diseases [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年九月五日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 (6) 複方電解質注射液(V) (500ml)，屬於化學藥品第3類，視同通過一致性評價。複方電解質注 射液主要用於成人作為水、電解質的補充源和鹼化劑;及 (7) 鹽酸左沙丁胺醇霧化吸入溶液(3ml: 0.63mg)，屬於化學藥品第3類，視同通過一致性評價。 鹽酸左沙丁胺醇霧化吸入溶液主要用於治療或預防成人及6歲以上兒童可逆性氣道阻塞性 疾病引起的支氣管痙攣。誠如本公司日期為二零二三年九月四日之公告所載，本集團的鹽 酸左沙丁胺醇原料藥已獲國家藥監局批准登記成為在上市製劑使用的原料藥。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本 ...

Group 1: R&D Investment and Achievements - In 2024, the company's R&D expenses reached CNY 56.53 million, representing a year-on-year increase of 13.19% [2] - Key R&D projects include the approval of the drug "Perindopril" in December 2024 and the development of "Maltose Iron Gel" [2] Group 2: Financial Performance - In 2024, the company achieved an operating income of CNY 847 million, a growth of 5.92% year-on-year, and a net profit attributable to shareholders of CNY 42.19 million, up 67.45% [5] - The increase in performance was driven by revenue growth, reduced financial expenses related to financial liabilities, and increased government subsidies [5] Group 3: Market Position and Future Plans - The company is focusing on multi-channel sales strategies for its smoking cessation drug, with expectations of continued high growth this year [6] - There are currently three companies competing in the domestic market for smoking cessation drugs [6] - The company has no current plans for mergers or acquisitions but will disclose any future plans promptly [6] Group 4: Shareholder Engagement and Financial Health - The decline in net assets is primarily due to the acquisition of minority shareholder equity in a subsidiary and obligations related to share buybacks [4] - The company emphasizes balancing profit distribution with reinvestment needs to enhance investor confidence [5]

Group 1: Financial Performance and Stock Management - The company has not considered stock buybacks or increases at this time, but will follow regulatory procedures if such plans arise [3] - The company acknowledges stock price fluctuations are influenced by various factors and aims to enhance operational performance to boost investor confidence [3] - The company reported a significant increase in revenue from its smoking cessation drug, with expectations for continued growth [4] Group 2: Product Development and Market Strategy - The company emphasizes the importance of research and development, with increasing investment in R&D over recent years [3] - New products are expected to be launched in the coming years, supported by funds raised through stock issuance in 2020 and 2021 [3] - The company plans to maintain a multi-channel marketing strategy to expand its market share and develop new business opportunities [4] Group 3: Cost Management and External Factors - To mitigate risks from raw material price fluctuations, the company will increase suppliers and improve production efficiency [2] - The impact of tariffs on the company's operations is minimal, as most business is domestic with only a small percentage of materials sourced from the U.S. [5] - The company does not anticipate new products entering the national procurement directory this year, as most of its main products are already included [5]